Atea Pharmaceuticals reported second quarter 2026 financial results and provided a business update. The company announced that its Phase 3 C-BEYOND trial for the HCV regimen BEM/RZR met primary and secondary endpoints, achieving a 93.9% sustained virologic response rate versus 94.8% for the comparator SOF/VEL in the modified intent-to-treat population. Cash and investments decreased to $219.5 million at June 30, 2026, from $301.8 million at year-end 2025. R&D expenses fell to $28.2 million from $32.3 million in the prior year period, resulting in a net loss of $32.9 million for the quarter. The company anticipates submitting an NDA to the FDA in Q2 2027 and expects C-FORWARD topline results in early Q1 2027. Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral diseases.